Related Experiment Video
Updated: Jan 2, 2026

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
Nectin-4 cis-interacts with ErbB2 and its trastuzumab-resistant splice variants, enhancing their activation and DNA
Shin Kedashiro1, Ayumu Sugiura1, Kiyohito Mizutani2
1From the Division of Pathogenetic Signaling, Department of Biochemistry and Molecular Biology, Kobe University Graduate School of Medicine, 1-5-6 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan.
Abstract:
Nectin-4 cell adhesion molecule and ErbB2 tyrosine kinase receptor are upregulated in many cancers, including breast cancer, and promote cancer cell proliferation and metastasis. Using human breast cancer cell lines T47D and SUM190-PT, in which both nectin-4 and ErbB2 were upregulated, we showed here that nectin-4 cis-interacted with ErB2 and enhanced its dimerization and activation, followed by the activation of the phosphoinositide 3-kinase-AKT signalling pathway for DNA synthesis. The third immunoglobulin-like domain of nectin-4 cis-interacted with domain IV of ErbB2. This region differs from the trastuzumab-interacting region but is included in the trastuzumab-resistant splice variants of ErbB2, p95-ErbB2 and ErbB2ΔEx16. Nectin-4 also cis-interacted with these trastuzumab-resistant splice variants and enhanced the activation of the phosphoinositide 3-kinase-AKT signalling pathway for DNA synthesis. In addition, nectin-4 enhanced the activation of the p95-ErbB2-induced JAK-STAT3 signalling pathway, but not the ErbB2- or ErbB2ΔEx16-induced JAK-STAT3 signalling pathway. These results indicate that nectin-4 cis-interacts with ErbB2 and its trastuzumab-resistant splice variants and enhances the activation of these receptors and downstream signalling pathways in a novel mechanism.
Insights
Nectin-4 interacts with ErbB2 and its resistant variants, activating cancer cell growth pathways. This discovery offers new insights into breast cancer mechanisms and potential therapeutic targets.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Biology
Background:
- Nectin-4 and ErbB2 are upregulated in cancers, promoting proliferation and metastasis.
- Understanding their interaction is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the cis-interaction between nectin-4 and ErbB2 in breast cancer cells.
- To elucidate the downstream signaling pathways activated by this interaction.
- To explore the role of nectin-4 in resistance to ErbB2-targeted therapies.
Main Methods:
- Utilized human breast cancer cell lines (T47D, SUM190-PT) with upregulated nectin-4 and ErbB2.
- Analyzed nectin-4 and ErbB2 dimerization and activation.
- Investigated the involvement of phosphoinositide 3-kinase-AKT and JAK-STAT3 signaling pathways.
Main Results:
- Nectin-4 cis-interacts with ErbB2, enhancing its dimerization and activating the PI3K-AKT pathway for DNA synthesis.
- Nectin-4 binds to the third immunoglobulin-like domain of nectin-4 and domain IV of ErbB2.
- Nectin-4 interacts with trastuzumab-resistant ErbB2 variants (p95-ErbB2, ErbB2ΔEx16), activating PI3K-AKT and JAK-STAT3 pathways.
Conclusions:
- Nectin-4 cis-interaction with ErbB2 and its resistant variants represents a novel mechanism for receptor activation.
- This interaction enhances downstream signaling, contributing to cancer progression.
- Nectin-4 may play a significant role in therapeutic resistance, suggesting it as a potential therapeutic target.
Related Concept Videos
Mitogens and the Cell Cycle
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Cadherins in Tissue Organization
Cell Sorting During Development
Cell sorting plays an...
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Abnormal Proliferation
Nucleotide Excision Repair

